CDK8与CD133在乳腺癌新辅助化疗疗效评价中的作用  

Effects of CDK8 and CD133 on evaluation of neo-adjuvant chemotherapy in breast cancer

作　　者：张坤[1] 吕旭 曹苏生[1] ZHANG Kun;LYU Xu;CAO Susheng(Department of Thyroid and Breast Surgery,Xuzhou Central Hospital,Xuzhou 221000,China;Department of Pathology,Xuzhou Central Hospital,Xuzhou 221000,China)

机构地区：[1]徐州市中心医院乳腺外科,江苏徐州221000 [2]徐州市中心医院病理科,江苏徐州221000

出　　处：《中国肿瘤外科杂志》2018年第6期368-371,共4页Chinese Journal of Surgical Oncology

基　　金：徐州市科技局社会发展项目(XXZD1346)

摘　　要：目的探讨CDK8与CD133在乳腺癌新辅助化疗疗效评价中的作用。方法选择2016年1月至2017年12月,徐州市中心医院临床Ⅱ、Ⅲ期原发性乳腺癌患者40例,行空芯针穿刺活检,病理证实为乳腺癌后予新辅助化疗至少3个周期,用免疫组化和蛋白质印迹法检测化疗前后标本CDK8与CD133的变化。结果新辅助化疗前后,TNM分期、肿瘤直径大小、淋巴结转移个数相比,差异有统计学意义(P<0. 05)。CDK8与CD133在乳腺癌中高表达,新辅助化疗后乳腺癌组织CDK8与CD133表达减少;癌旁正常乳腺组织及纤维腺瘤组织CDK8和CD133表达量均低于新辅助化疗前乳腺癌组织(均P<0. 05)。新辅助化疗前后,CDK8和CD133变化一致,且与疗效变化一致。结论 CDK8与CD133可作为新辅助化疗疗效预测因子。Objective To study the effects of CDK8and CD133on the evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer.Methods A total of40patients with primary breast cancer in clinical stageⅡandⅢreceived core needle biopsy.They were given neoadjuvant chemotherapy for at least3cycles after been confirmed as breast cancer by pathology.The changes of CDK8and CD133were detected by immunohistochemical and Western blotting methods before and after chemotherapy.Results The difference was statistically significant between TNM staging,tumor diameter and the number of lymph node metastases before and after neoadjuvant chemotherapy(P<0.05).The expression of CDK8and CD133in breast cancer was high,and the decrease of CDK8and CD133in neoadjuvant chemotherapy was obvious,and the expression of CDK8and CD133in normal tissues and fibrous adenoma of cancer was lower than that of breast cancer tissues before neoadjuvant chemotherapy(all P<0.05).The changes of CDK8and CD133were consistent before and after neoadjuvant chemotherapy,and were consistent with the change of curative effect.Conclusions CDK8and CD133can be used as predictors of the efficacy of neoadjuvant chemotherapy,and thus is deserving clinical application.

关 键 词：乳腺癌 CDK8 CD133 新辅助化疗 疗效 

分 类 号：R737.9[医药卫生—肿瘤]